

DOCKET NO.: AREN-03203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Chen W. Liaw, et al.

Serial No.: 10/083,168

Filing Date: February 26, 2002

Group Art Unit: 1646

Examiner: Not Yet Assigned

For: ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G  
PROTEIN-COUPLED RECEPTORS

COPY OF PAPERS  
ORIGINALLY FILED

DATE OF DEPOSIT: May 21, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID  
ON THE DATE INDICATED ABOVE AND IS ADDRESSED  
TO THE ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, DC 20231.

TYPED NAME: Gwilym J.O. Attwell  
REGISTRATION NO.: 45,449

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

#### INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).



In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

GP/1646 #5  
B  
6/12/02  
RECEIVED  
JUN 05 2002  
TECH CENTER 1600/2900

MAILED CANCELLED  
MAY 8 2002  
O I P E  
MAY 2 9 2002  
TRADEMARK OFFICE

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☒ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:

☒ Copies of references **AA thru HS** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 09/170,496, filed **October 13, 1998**.


☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.


This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: *May 21, 2002*

  
Gwilym J.O. Attwell  
Registration No. 45,449

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



RECEIVED  
JUN 05 2002  
TECH CENTER 1600/2900f18

<b>Form PTO-1449 Modified</b>		Docket No. <b>AREN-0320</b>	Serial No. <b>10/083,168</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Chen W. Liaw et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>February 26, 2002</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>AA</b>	Alla, S.A. et al., "Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies," <i>J. Biol. Chem.</i> , <b>1996</b> , 271, 1748-1755	
	<b>AB</b>	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK <sub>2</sub> ) receptors," <i>Am. Rev. Respir. Dis.</i> , <b>1992</b> , 146(5, Pt. 1), 1177-1181	
	<b>AC</b>	Alexander, W.S. et al., "Point mutations within the dimer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , <b>1995</b> , 14(22), 5569-5578	
	<b>AD</b>	Arvanitakis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , <b>1997</b> , 385, 347-349	
	<b>AE</b>	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , <b>1994</b> , 269(16), 11687-11690	
	<b>AF</b>	Baxter, G., "5-HT <sub>2</sub> receptors: a family re-united?" <i>Trends Pharmacol. Sci.</i> , <b>1995</b> , 16, 105-110	
	<b>AG</b>	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family," <i>Nature</i> , <b>1986</b> , 320, 415	
	<b>AH</b>	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G <sub>q/11</sub> by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , <b>1995</b> , 270, 17741-17748	
	<b>AI</b>	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, <b>1998</b> , 363-377	
	<b>AJ</b>	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , 90(21), 9921-9925	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

COPY OF PAPERS  
ORIGINALY FILED

OIPE  
 MAY 28 2002  
 MAIL DAY  
 CANC

OIPE  
 MAY 29 2002  
 PATENT & TRADEMARK OFFICE

RECEIVED

JUN 05 2002

TECH CENTER 1600/2900 2 of 18



<b>Form PTO-100 Modified</b>		<b>Docket No.</b> <b>AREN-0320</b>	<b>Serial No.</b> <b>10/083,168</b>
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Chen W. Liaw et al.</b>	
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>February 26, 2002</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
AK	Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," <i>Biochem. Pharmacol.</i> , <b>1996</b> , 51(4), 539-544		
AL	Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(6), 2882-2885		
AM	Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein G <sub>q</sub> ," <i>FEBS Lett.</i> , <b>1995</b> , 363(3), 261-263		
AN	Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," <i>Pharmacol. Rev.</i> , <b>1994</b> , 46, 121-136		
AO	Casey, C. et al., "Constitutively active mutant 5-HT <sub>2A</sub> serotonin receptors: inverse agonist activity of classical 5HT <sub>2A</sub> antagonists," <i>Soc. Neurosci.</i> , <b>1996</b> , Abstract #699.10		
AP	Cheatham, B. et al., "Substitution of the <i>erbB-2</i> oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , 90, 7336-7340		
AQ	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," <i>J. Biol. Chem.</i> , <b>1995</b> , 270, 23398-23401		
AR	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," <i>J. Antibiot. (Tokyo)</i> , <b>1993</b> , 46(1), 131-134		
AS	Chen, W. et al., "A colorimetric assay for measuring activation of G <sub>s</sub> - and G <sub>q</sub> -coupled signaling pathways," <i>Anal. Biochem.</i> , <b>1995</b> , 226(2), 349-354		
AT	Chidiac, P. et al., "Inverse agonist activity of $\beta$ -adrenergic antagonists," <i>J. Pharm. Exp. Ther.</i> , <b>1994</b> , 45, 490-499		
AU	Clozel, M. et al., "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," <i>J. Cardiovas. Pharmacol.</i> , <b>1993</b> , 22(Suppl. 8), S377-S379		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

COPY OF PAPERS  
 ORIGINALLY FILED

RECEIVED

JUN 05 2002

TECH CENTER 1600/290018



Form PTO-1449 Modified

Basket No.  
AREN-0320Serial No.  
10/083,168List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
Chen W. Liaw et al.U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
February 26, 2002Group  
1646



## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AV	Collesi, C. et al., "A splicing variant of the <i>RON</i> transcript induces constitutive tyrosine kinase activity and an invasive phenotype," <i>Mol. Cell. Biol.</i> , <b>1996</b> , 16(2), 5518-5526
AW	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , <b>1984</b> , 311, 29-33
AX	De Dios, I. et al., "Effect of L-364,718 (CCK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats," <i>Pancreas</i> , <b>1994</b> , 9(2), 212-218
AY	Desbios-Mouthon, C. et al., "Deletion of Asn <sup>281</sup> in the $\alpha$ -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , <b>1996</b> , 81(2), 719-727
AZ	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , <b>1991</b> , 6(11), 1997-2003
BA	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," <i>Oncogene</i> , <b>1992</b> , 7, 2549-2553
BB	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism," <i>Nature Genetics</i> , <b>1994</b> , 7, 396-401
BC	Eggericksx, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , <b>1995</b> , 309, 837-843
BD	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," <i>J. Med. Chem.</i> , <b>1992</b> , 35, 3919-3927
BE	Fu, M. et al., "Functional autoimmune epitope on $\alpha_1$ -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , <b>1994</b> , 344, 1660-1663
BF	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto-oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of c-kit Product," <i>J. Clin. Invest.</i> , <b>1993</b> , 92, 1736-1744
BG	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," <i>J. Pharm. Exp. Therap.</i> , <b>1995</b> , 275(1), 200-206

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

JUN 05 2002

TECH CENTER 1600/2300 of 18



Form PT-144 Modified

Docket No.  
AREN-0320Serial No.  
10/083,168List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
Chen W. Liaw et al.U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
February 26, 2002Group  
1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BH	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , <b>1995</b> , 275(2), 737-744
BI	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , <b>1996</b> , 87(5), 1692-1697
BJ	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel $\gamma$ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , <b>1995</b> , 11(1), 76-82
BK	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(4), 1857-1860
BL	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," <i>J. Clin. Invest.</i> , <b>1984</b> , 74, 647-651
BM	Herrick-Davis, K. et al., "Constitutively Active 5HT <sub>2C</sub> Serotonin Receptor Created by Site-Directed Mutagenesis," <i>Soc. Neurosci.</i> , Abstract No. 699.18
BN	Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , <b>1995</b> , 47, 267-270
BO	Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," <i>Am. Soc. Pharm. Exp. Therap.</i> , <b>1990</b> , 42(1), 45-83
BP	Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," <i>J. Biol. Chem.</i> , <b>1995</b> , 270(13), 7405-7410
BQ	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene <i>c-kit</i> in Acute Myeloblastic Leukemia Cells," <i>Blood</i> , <b>1991</b> , 78(11), 2962-2968
BR	Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," <i>Mol. Pharm.</i> , <b>1992</b> , 42, 982-990
EXAMINER	
DATE CONSIDERED	

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

JUN 05 2002

TECH CENTER 1600/2900 of 18

## Form PTO-140 (Modified)

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
AREN-0320

Serial No.  
10/083,168

Applicant  
Chen W. Liaw et al.

Filing Date  
February 26, 2002

Group  
1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)



BS	Jakubik, J. et al., "Constitutive activity of the M <sub>1</sub> -M <sub>4</sub> subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," <i>FEBS Letts.</i> , 1995, 377, 275-279
BT	Kjelsberg, M.A. et al., "Constitutive activation of the $\alpha_{1B}$ -adrenergic receptor by all amino acid substitutions at a single site," <i>J. Biol. Chem.</i> , 1992, 267(3), 1430-1433
BU	Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," <i>FASEB J.</i> , 1995, 9, 516-525
BV	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , 1995, 4(2), 183-188
BW	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , 1993, 7, 114-130
BX	Kraus, M. et al., "Demonstration of ligand-dependent signaling by the <i>erbB-3</i> tyrosine kinase and its constitutive activation in human breast tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 2900-2904
BY	Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," <i>J. Pharm. Exp. Therap.</i> , 1996, 277(2), 840-851
BZ	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene <i>c-kit</i> Product," <i>Blood</i> , 1991, 78(11), 2834-2840
CA	Labbe-Jullie, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," <i>J. Pharm. Exp. Therap.</i> , 1994, 271(1), 267-276
CB	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," <i>J. Clin. Endocrinol. Metab.</i> , 1995, 80(8), 2490-2494

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED





RECEIVED

JUN 05 2002

TECH CENTER 1600/2500 Sheet 6 of 18

## Form PTO-1485 Modified

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
AREN-0320

Serial No.  
10/083,168

Applicant  
Chen W. Liaw et al.

Filing Date  
February 26, 2002

Group  
1646


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CC	Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," <i>Proc. Natl. Acad. Sci USA</i> , 1995, 92, 1906-1910
CD	Løvlie, R. et al., "The Ca <sup>2+</sup> -sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," <i>Hum. Genet</i> , 1996, 98, 129-133
CE	Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," <i>Trends Pharmacol. Sci.</i> , 1993, 14, 300-307
CF	Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," <i>Nature</i> , 1985, 313, 144-147
CG	Liu, C. et al., "Overexpression of <i>c-met</i> proto-oncogene but not epidermal growth factor receptor or <i>c-erbB-2</i> in primary human colorectal carcinomas," <i>Oncogene</i> , 1992, 7, 181-185
CH	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," <i>J. Biol. Chem.</i> , 1996, 271(11), 6172-6178
CI	Lonardo, F. et al., "The normal <i>erbB-2</i> product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , 1990, 2(11), 992-1003
CJ	Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , 1990, 173(3), 1169-1178
CK	Mann, J. et al., "Increased serotonin <sub>2</sub> and $\beta$ -adrenergic receptor binding in the frontal cortices of suicide victims," <i>Arch. Gen. Psychiatry</i> , 1986, 43, 954-959
CL	Marone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8
CM	Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," <i>Circulation</i> , 1994, 89, 2760-2767

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALY FILED



RECEIVED

JUN 05 2002

TECH CENTER 1600/2900 Sheet 7 of 18

Form PTO-1449 Modified

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
AREN-0320

Serial No.  
10/083,168

Applicant  
Chen W. Liaw et al.

Filing Date  
February 26, 2002

Group  
1646


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CN	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , 1995, 270(3), 1041-1047
CO	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , 1994, 14(7), 4843-4854
CP	Nanevicz, T. et al., "Thrombin receptor activating mutations," <i>J. Biol. Chem.</i> , 1996, 271(2), 702-706
CQ	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , 1993, 68, 746-750
CR	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," <i>J. Biol. Chem.</i> , 1995, 270(44), 26037-26040
CS	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," <i>J. Pharm. Exp. Ther.</i> , 1992, 263(1), 241-245
CT	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human $\beta$ 2-adrenergic receptor," <i>J. Biol. Chem.</i> , 1988, 263(31), 15985-15992
CU	Offermanns, S. et al., " $G\alpha_{15}$ and $G\alpha_{16}$ Couple a Wide Variety of Receptors to Phospholipase C," <i>J. Biol. Chem.</i> , 1995, 270, 15175-15180
CV	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," <i>J. Med. Chem.</i> , 1994, 37, 4508-4521
CW	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," <i>J. Biol. Chem.</i> , 1996, 271(14), 7949-7955
CX	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," <i>J. Clin. Endocr. Metab.</i> , 1996, 81, 3584-3588

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

JUN 05 2002

TECH CENTER 1600/2900  
Sheet 8 of 18

Form PTO-100 Modified

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**AREN-0320**

Serial No.  
**10/083,168**

Applicant  
**Chen W. Liaw et al.**

Filing Date  
**February 26, 2002**

Group  
**1646**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

CY	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , 1993, 365, 649-651
CZ	Pei, G. et al., "A constitutive active mutant $\beta_2$ -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 2699-2702
DA	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , 1993, 265(3), 1348-1354
DB	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," <i>CNS Drugs</i> , 1995, 4 (Suppl. 1), 18-28
DC	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , 1993, 45, 289-293
DD	Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," <i>Int. J. Cancer</i> , 1991, 49, 323-328
DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , 1996, 49, 422-429
DF	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and $^3\text{H}$ -acetylcholine release from guinea-pig gallbladder," <i>Neuropeptides</i> , 1993, 25(5), 271-276
DG	Ren, Q. et al., "Constitutive active mutants of the $\alpha_2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268, 16483-16487
DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active $\text{ET}_A$ receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273(3), 1410-1417
DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , 1993, 72, 827-834
DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," <i>Cancer</i> , 1993, 53(22), 5355-5360

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

JUN 05 2002

TECH CENTER 1600/2900

Sheet 9 of 18

## Form PTO-1449 Modified

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
AREN-0320

Serial No.  
10/083,168

Applicant  
Chen W. Liaw et al.

Filing Date  
February 26, 2002

Group  
1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

DK	Samama, P. et al., "A mutation-induced activation state of the $\beta$ 2-adrenergic receptor," <i>J. Biol. Chem.</i> , 1993, 268(7), 4625-4636
DL	Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," <i>Am. Soc. Pharm. Exp. Ther.</i> , 1996, 50, 285-292
DM	Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73, 805-811
DN	Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Rec. Signal Transduct. Res.</i> , 1997, 17(1-3), 57-73
DO	Scheer, A. et al., "The activation process of the $\alpha_{1B}$ -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," <i>Proc. Natl. Acad. Sci. USA</i> , 1997, 94, 808-813
DP	Schwinn, D.A. et al., "Cloning and pharmacological characterization of human <i>Alpha</i> -1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," <i>J. Pharmacol.</i> , 1995, 272(1), 134-142
DQ	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , 1995, 92, 5699-5703
DR	Seeman, P. et al., "Dopamine receptor pharmacology," <i>Trends Pharmacol. Sci.</i> , 1994, 15, 264-270
DS	Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," <i>Nature</i> , 1993, 365, 441-445
DT	Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin $V_{1a}$ receptors," <i>J. Clin. Invest.</i> , 1993, 92, 224-231
DU	Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," <i>Mol. Cell. Endocrinology</i> , 1994, 100, 115-119

EXAMINER

DATE CONSIDERED



COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

JUN 05 2002

TECH CENTER 1600/2900

Sheet 10 of 18

**Form PTO-1449 Modified**Docket No.  
**AREN-0320**Serial No.  
**10/083,168**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
**Chen W. Liaw et al.**U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
**February 26, 2002**Group  
**1646****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<b>DV</b>	Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," <i>Blood</i> , <b>1992</b> , 80(12), 3070-3078
<b>DW</b>	Skinner, R.H. et al., "Direct measurement of the binding of RAS to neurofibromin using scintillation proximity assay," <i>Anal. Biochem.</i> , <b>1994</b> , 223, 259-265
<b>DX</b>	Slamon, D.J. et al., "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ <i>neu</i> oncogene," <i>Science</i> , <b>1987</b> , 235, 177-182
<b>DY</b>	Slamon, D. et al., "Studies of the HER-2/ <i>neu</i> proto-oncogene in human breast and ovarian cancer," <i>Science</i> , <b>1989</b> , 244, 707-712
<b>DZ</b>	Solomon, Y. et al., "A highly sensitive adenylate cyclase assay," <i>Anal. Biochem.</i> , <b>1974</b> , 58, 541-548
<b>EA</b>	Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," <i>Ann. Rev. Physiol.</i> , <b>1995</b> , 58, 143-170
<b>EB</b>	ter Laak, A. et al., "Modelling and mutation studies on the histamine H <sub>1</sub> -receptor agonist binding site reveal different binding modes for H <sub>1</sub> -agonists: Asp <sup>116</sup> (TM3) has a constitutive role in receptor stimulation," <i>J. Computer-Aided Mol. Design</i> , <b>1995</b> , 9, 319-330
<b>EC</b>	Tiberi, M. et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype," <i>J. Biol. Chem.</i> , <b>1994</b> , 269(45), 27925-27931
<b>ED</b>	Tsujimura, T. et al., "Constitutive activation of <i>c-kit</i> in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain," <i>Blood</i> , <b>1996</b> , 87(1), 273-283
<b>EE</b>	Wang, Z. et al., "Constitutive $\mu$ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence," <i>Life Sci.</i> , <b>1994</b> , 54(20), 339-350
<b>EF</b>	Watowich, S.S. et al., "Homodimerization and constitutive activation of the erythropoietin receptor," <i>Proc. Natl. Acad. Sci USA</i> , <b>1992</b> , 89, 2140-2144

**EXAMINER****DATE CONSIDERED**COPY OF PAPERS  
ORIGINALLY FILED

OTPE  
MAY 28 2002  
MAY 28 2002  
MAY 28 2002

MAY 28 2002  
PATENT & TRADEMARK OFFICE


RECEIVED

JUN 05 2002

TECH CENTER 1600/2900  
Sheet 11 of 18

Form PTO-151 Modified		Docket No. AREN-0320	Serial No. 10/083,168
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Applicant Chen W. Liaw et al.	
		Filing Date February 26, 2002	Group 1646
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
EG	Weber-Nordt, R.M. et al., "Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines," <i>Blood</i> , 1996, 88(3), 809-816		
EH	Webster, M.K. et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane point mutation found in achondroplasia," <i>EMBO J.</i> , 1996, 15, 520-527		
EI	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , 1984, 81, 7308-7312		
EJ	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinas <i>in vitro</i> ," <i>J. Biol. Chem.</i> , 1992, 267(18), 12452-12461		
EK	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Opioid Receptor-Like Orphan Receptor," <i>J. Biol. Chem.</i> , 1995, 270, 22772-22778		
EL	Zhen, Z. et al., "Structural and functional domains critical for constitutive activation of the HGF-receptor ( <i>Met</i> )," <i>Oncogene</i> , 1994, 9, 1691-1697		
EM	Pauwles, P.J. et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors", <i>Molecular Neurobiology</i> , 1998, 17, 109-135		
EN	Shryock, J. et al., "Inverse Agonists and Neutral Antagonists of Recombinant Human A1 Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells", <i>Molecular Pharmacology</i> , 1998, 53, 886-893		
EO	Wenzel-Seifert, et al., "High Constitutive Activiy of the Human Fromyl Peptide Receptor", <i>Journal of Biological Chem.</i> , 1998, 273, 24181-24189		
EP	Forman, B.M. et al., "Androstane Metabolites Bind to and Deactivate the Nuclear Receptor CAR-β", <i>Nature</i> , 1998, 395, 612-615		
EQ	Seifert, R. et al., "different Effects of Gsβ Splice Variants on β2-Adrenoreceptor-mediated Signaling, <i>Jrl. of Biological Chem.</i> , 1998, 273, 5109-5116		
EXAMINER		DATE CONSIDERED	

COPY OF PAPER  
ORIGINALLY FILED



RECEIVED

JUN 05 2002

TECH CENTER 1600/2500 Sheet 12 of 18

Form PTO-149 Modified

Docket No.  
AREN-0320Serial No.  
10/083,168List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)Applicant  
Chen W. Liaw, et al.U.S. Department of Commerce  
Patent and Trademark OfficeFiling Date  
February 26, 2002Group  
1646


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ER	Abola, A.P., et al., "Omo sapiens chromosome 13 clone RP11-286P8, complete sequence," AC026756 XP-002175912, April 24, 2000, 1-41
ES	Adams, M.D., et al., "CIT-HSP-2286K19.TF CIT-HSP homo sapiens genomic clone 2286K19, genomic survey sequence," AQ001459, XP-002175783, August 24, 2001, 1 page
ET	Birren, B., et al., "Homo sapiens chromosome 11, clone RP11-589F4," AC027026, XP002175913, April 27, 2000, 1-40
EU	Birren, B., et al., "Homo sapiens clone RP11-15H8, 31 unordered pieces," AC011780, XP002175781, October 18, 1999, 1-46
EV	Birren, B., et al., "Homo sapiens clone RP11-14N15," AC016468, XP002175784, December 1, 1999, 1-38
EW	Boyer, J.L., et al., "Molecular cloning and expression of an avian G protein-coupled P2Y receptor," <i>Am. Soc. For Pharmacology &amp; Experimental Therapeutics</i> , XP-002175907, 1997, 928-934
EX	Burton, J., et al., "Human DNA sequence from clone RP11-163L4," A1161458, XP002175911, April 16, 2000, 1-39
EY	Burton, J., "Human DNA sequence from clone RP11-15909," AL136106, XP002175785, January 7, 2000
EZ	Collier, R., "DJ68ON, 3 (G-protein coupled receptors) (fragment)," Accession Nr. Q9NTTO, XP002168498, January 10, 2001, 1 page
FA	Doe Joint Genome Institute, "Homo sapiens chromosome 5 clone CTC-502M5, complete sequence," AC008547, XP002175786, August 4, 1999, 1-30

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED

**RECEIVED**

JUN 05 2002

TECH CENTER 1600/2900

Sheet 13 of 18

**Form PTO-1449 Modified**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
**AREN-0320**Serial No.  
**10/083,168**Applicant  
**Chen W. Liaw, et al.**Filing Date  
**February 26, 2002**Group  
**1646****OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<b>FB</b>	Doe Joint Genome Institute, "Homo sapiens chromosome 19 clone CTD-3023J11, complete sequence," AC008754, XP002175778, August 4, 1999, 1-18
<b>FC</b>	Doe Joint Genome Institute, "Sequencing of human chromosome 5," AC008728, XP002175776, August 4, 1999, 1-42
<b>FD</b>	Gempscue, "Drosophila melanogaster genome survey sequence TET3 end of BAC # BACRO8K10 of RPCI-98 library from drosophila melanogaster (fruit fly)," AL065769, XP00217590
<b>FE</b>	Hattori, M., et al., "Homo sapiens 171, 539 genomic of 11q13," AP000808, XP002175780, December 3, 1999, 1-45
<b>FF</b>	Heise, C.E., et al., "Characterization of the human cysteinyl leukotriene 2 receptor," <i>J. Biological Chemistry</i> , September 29, 2000, 275(39), 30531-30536
<b>FG</b>	Kjelsberg, M.A., et al., "constitutive activation of the $\alpha_{1B}$ -adrenergic receptor by all amino acid substitutions at a single site," <i>J. Biological Chemistry</i> , XP-002135768, 1992, 265(3), 1430-1433
<b>FH</b>	Mahairas, G.G., et al., "Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome," <i>Proc. Natl. Acad. Sci. USA</i> , August 1999, 96, 9739-9744
<b>FI</b>	Marchese, A., et al., "Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology," <i>TiPS</i> , September 1999, 20, 370-375
<b>FJ</b>	O'Dowd, B.F., et al., "Discovery of three novel G-protein-coupled receptor genes," <i>Genomics</i> , XP-000863786, 1998, 310-313
<b>FK</b>	Ohono, M., et al., "Homo sapiens mRNA for G protein-coupled receptor C5L2, complete cds," AB038237, XP002175947, May 4, 2000, 1 page
<b>FL</b>	Stadel, J.M., et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery," <i>TiPS</i> , November 1997, 18, 430-437
<b>EXAMINER</b>	
<b>DATE CONSIDERED</b>	

COPY OF PAPERS  
ORIGINALLY FILED





● RECEIVED

JUN 05 2002

TECH CENTER 1600/2900

Sheet 14 of 18

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**AREN-0320**

Serial No.  
**10/083,168**

Applicant  
**Chen W. Liaw, et al.**

Filing Date  
**February 26, 2002**

Group  
**1646**


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

FM	Stone, N., et al., "Homo sapiens chomosome 4, 16 unordered pieces," AC007104, XP002175914, April 23, 1999, 1-52
FN	Wallis, J., "Human DNA sequence from clone RP5-1160K1," AL355310, XP002175782, May 5, 2000, 1-39
FO	Waterson, R.H., "homo sapiens chromosome 2 clone RP11-510c1," AC010984, XP002175915, September 29, 1999, 1-50
FP	Weinshank, R.H., "5-hydroxytryptamine 1B receptor (-HT-1B) (serotonin receptor)," AC 008892, XP002175948, July 15, 1998, 1 page
FQ	Zhao, S., et al., "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," AQ532303, XP002175779, May 18, 1999, 1 page
FR	PCT International Search Report dated September 19, 2001
FS	Watson, S. et al., "The G-Protein linked receptor facts book", <i>Academic Press</i> , 2-6, 162-169
FT	Rudinger, J. et al., <i>Peptide Hormones</i> , J.A. Parsons, Unoversity Park Press, Baltimore, 1-7

**EXAMINER**

**DATE CONSIDERED**

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

JUN 05 2002  
Sheet 15 of 18

TECH CENTER 1600/2900  
Serial No. 09/170,496

Form BTQ-1449 Modified

Docket No.  
AREN-0040

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

Applicant  
Liaw, et al.

U.S. Department of Commerce  
Patent and Trademark Office

Filing Date  
October 13, 1998

Group  
1646



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

FU	Bergsma, D.J., et al., "Cloning and characterization of a human angiotensin II type 1 receptor," <i>Biochem. &amp; Biophys. Res. Comm.</i> , 1992, XP-002145165, 183(3), 989-995
FV	Gantz, I., et al., "Molecular cloning, expression, and gene localization of a fourth melanocortin receptor," <i>J. Biol. Chem.</i> , 1993, XP-002051983, 268(20), 15174-15178
FW	Groblewski, T., et al., "Mutation of Asn <sup>111</sup> in the third transmembrane domain of the AT <sub>1a</sub> angiotensin II receptor induces its constitutive activation," <i>J. Biol. Chem.</i> , 1997, XP-002145162, 272(3), 1822-1826
FX	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophys. Res. Comm.</i> , 1994, XP-002145166, 203(3), 1842-1850
FY	Kyaw, H., et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene," <i>DNA and Cell Biology</i> , 1998, XP000929737, 17(6), 493-500
FZ	Noda, K., et al., "The active state of the AT <sub>1</sub> angiotensin receptor is generated by angiotensin II induction," <i>Biochem.</i> , 1996, XP-002145163, 35, 16435-16442
GA	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , 1996, XP-002145161, 219-2254
GB	Scheer, A., et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Receptor &amp; Signal Transduction Res.</i> , 1997, XP-000867531, 17(1-3), 57-73

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

JUN 05 2002

TECH CENTER 1600/2900  
Sheet 16 of 18

## Form PTO-144 Modified

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
AREN-0320Serial No.  
10/083,168Applicant  
Chen W. Liaw, et al.Filing Date  
February 26, 2002Group  
1646

## U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	GC	5,861,309	01/19/99	Bard, et al.	135	325
	GD	5,891,720	04/06/99	Moore, et al.	435	325
	GE	5,955,308	09/21/99	Bergsma, et al.	435	69.1

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	GF	WO 96/05302	02/22/96	PCT		
	GG	WO 97/21731	06/19/97	PCT		
	GH	WO 98/29439	07/09/98	PCT		
	GI	WO 98/46620	10/22/98	PCT		
	GJ	WO 98/56820	12/17/98	PCT		
	GK	WO 99/06552	02/11/99	PCT		
	GL	WO 99/32519	07/01/99	PCT		
	GM	WO 99/48921	09/30/99	PCT		
	GN	WO 00/14229	03/16/00	PCT	X (abstract)	
	GO	WO 00/22131	04/20/00	PCT		
	GP	WO 00/49046	08/24/00	PCT	X (abstract)	
	GQ	WO 01/07606 A1	02/01/01	PCT		
	GR	WO 01/09184 A1	02/08/01	PCT		
	GS	WO 01/12673 A1	02/22/01	PCT		

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED



JUN 05 2002

TECH CENTER 1600/2900  
Sheet 17 of 18

**Docket No.**  
**AREN-0320**

Serial No.  
10/083,168

**Applicant**  
**Chen W. Liaw, et al.**

U.S. Department of Commerce  
Patent and Trademark Office


**Filing Date**  
**February 26, 2002**

**Group  
1646**

## FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	GT	WO 01/14577 A1	03/01/01	PCT		
	GU	WO 01/16159 A1	03/08/01	PCT		
	GV	WO 01/31014 A2	05/03/01	PCT		
	GW	WO 01/36471 A2	05/25/01	PCT		
	GX	0 612 845 A2	08/31/94	EPO		
	GY	0 878 542 A2	11/18/98	EPO		
	GZ	0 892 051 A2	01/20/99	EPO		
	HA	1 090 989 A1	04/11/01	EPO		
	HB	1 094 076 A1	04/25/01	EPO		
	HC	8-245697	09/24/99	Japan		X
	HD	11-32770	02/09/99	Japan		X
	HE	11-98988	09/13/99	Japan	X (abstract)	
EXAMINER				DATE CONSIDERED		

**COPY OF PAPERS  
ORIGINALLY FILED**



RECEIVED  
JUN 05 2002  
TECH CENTER 1608/2908

Form PTO-1449 Modified

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
AREN-0320

Serial No.  
10/083,168

Applicant  
Chen W. Liaw et al.

Filing Date  
February 26, 2002

Group  
1646

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	HF	5,514,578	05/07/96	Hogness et al.	435	240.2
	HG	5,532,157	07/02/96	Fink	435	240.2
	HH	5,573,944	11/12/96	Kirschner et al.	435	252.3
	HI	5,639,616	06/17/97	Liao et al.	435	7.1
	HJ	5,750,353	05/12/98	Kopin et al.	435	7.21

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	HK	WO 97/11159	09/20/96	PCT	X	
	HL	WO 97/21731 A	06/19/97	PCT	X	
	HM	WO 98/38217 A	09/03/98	PCT	X	
	HN	WO 98/46995	10/22/98	PCT	X	
	HO	WO 99/52927	10/21/99	PCT	X	
	HP	WO 98/00552	01/08/98	PCT	X	
	HQ	WO 98/34948	08/13/98	PCT	X	
	HR	WO/99 24569	05/20/99	Japan	X	
	HS	2,135,253	08/05/96	Canada	X	

EXAMINER

DATE CONSIDERED

COPY OF PAPERS  
ORIGINALLY FILED